Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database
Marta Bini
(1, 2)
,
Stanislas Quesada
(1, 3)
,
Pierre Méeus
(1)
,
Manuel Rodrigues
(4)
,
Eric Leblanc
(5)
,
Anne Floquet
(6)
,
Patricia Pautier
(7)
,
Frédéric Marchal
(8)
,
Magali Provansal
(9)
,
Loïc Campion
(10)
,
Sylvain Causeret
(11)
,
Sophie Gourgou
(3)
,
Isabelle Ray-Coquard
(1)
,
Jean-Marc Classe
(10)
,
Christophe Pomel
(12, 13)
,
Thibault de La Motte Rouge
(14)
,
Emmanuel Barranger
(15)
,
Aude Marie Savoye
(16)
,
Cécile Guillemet
(17)
,
Laurence Gladieff
(18)
,
Martin Demarchi
(19)
,
Roman Rouzier
(20)
,
C Courtinard
(21)
,
Clémence Romeo
(1)
,
Florence Joly
(20)
1
Centre Léon Bérard [Lyon]
2 IRCCS Istituto Nazionale dei Tumori [Milano]
3 ICM - Institut régional de Cancérologie de Montpellier
4 Institut Curie [Paris]
5 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
6 Institut Bergonié [Bordeaux]
7 IGR - Institut Gustave Roussy
8 UNICANCER/ICL - Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy]
9 IPC - Institut Paoli-Calmettes
10 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]
11 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
12 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
13 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
14 CRLCC - CRLCC Eugène Marquis
15 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
16 Institut Jean Godinot [Reims]
17 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
18 ICR - Institut Claudius Regaud
19 ICANS - Institut de Cancérologie de Strasbourg Europe
20 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
21 UNICANCER
2 IRCCS Istituto Nazionale dei Tumori [Milano]
3 ICM - Institut régional de Cancérologie de Montpellier
4 Institut Curie [Paris]
5 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
6 Institut Bergonié [Bordeaux]
7 IGR - Institut Gustave Roussy
8 UNICANCER/ICL - Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy]
9 IPC - Institut Paoli-Calmettes
10 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]
11 UNICANCER/CRLCC-CGFL - Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon]
12 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
13 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
14 CRLCC - CRLCC Eugène Marquis
15 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
16 Institut Jean Godinot [Reims]
17 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
18 ICR - Institut Claudius Regaud
19 ICANS - Institut de Cancérologie de Strasbourg Europe
20 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
21 UNICANCER
Stanislas Quesada
- Fonction : Auteur
- PersonId : 1192570
- ORCID : 0000-0001-6338-9306
Manuel Rodrigues
- Fonction : Auteur
- PersonId : 769887
- ORCID : 0000-0002-5443-0802
Eric Leblanc
- Fonction : Auteur
- PersonId : 767838
- ORCID : 0000-0001-7299-0339
- IdRef : 071219269
Loïc Campion
- Fonction : Auteur
- PersonId : 761946
- ORCID : 0000-0003-4903-0908
- IdRef : 169128628
Isabelle Ray-Coquard
- Fonction : Auteur
- PersonId : 760354
- ORCID : 0000-0003-2472-8306
Jean-Marc Classe
- Fonction : Auteur
- PersonId : 1192571
- ORCID : 0000-0002-6167-5832
- IdRef : 112048234
Martin Demarchi
- Fonction : Auteur
- PersonId : 1145374
- ORCID : 0000-0003-1894-3560
Roman Rouzier
- Fonction : Auteur
- PersonId : 1181823
- ORCID : 0000-0002-8167-6808
- IdRef : 077207505
Clémence Romeo
- Fonction : Auteur
- PersonId : 824097
- ORCID : 0000-0003-1280-8069
Résumé
Background: In spite of the frequency and clinical impact of BRCA1/2 alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date. Methods: Consecutive patients with BRCA-mutated HGEOC treated between 2011 and 2016 within French comprehensive cancer centers from the Unicancer network were extracted from the ESME database. The main objective of the study was the assessment of clinicopathological and treatments parameters. Results: Out of the 8021 patients included in the ESME database, 266 patients matching the selection criteria were included. BRCA1 mutation was found in 191 (71.8%) patients, while 75 (28.2%) had a BRCA2 mutation only; 95.5% of patients received a cytoreductive surgery. All patients received a taxane/platinum-based chemotherapy (median = six cycles). Complete and partial response were obtained in 53.3% and 20.4% of the cases, respectively. Maintenance therapy was administered in 55.3% of the cases, bevacizumab being the most common agent. After a median follow up of 51.7 months, a median progression-free survival of 28.6 months (95% confidence interval (CI) [26.5; 32.7]) and an estimated 5-year median overall survival of 69.2% (95% CI [61.6; 70.3]) were reported. Notably, BRCA1- and BRCA2-mutated cases exhibited a trend towards different median progression-free survivals, with 28.0 (95% CI [24.4; 32.3]) and 33.3 months (95% CI [26.7; 46.1]), respectively (p-value = 0.053). Furthermore, five-year OS for BRCA1-mutated patients was 64.5% (95% CI [59.7; 69.2]), while it was 82.5% (95% CI [76.6; 88.5]) for BRCA2-mutated ones (p-value = 0.029). Conclusions: This study reports the largest French multicenter cohort of BRCA-mutated HGEOCs based on robust data from the ESME, exhibiting relevant real-world data regarding this specific population.
